

Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Complete if Known</i>	
		Application Number	10/598,449
		Filing Date	August 30, 2006
		First Named Inventor	Aissaoui
		Art Unit	1614
		Examiner Name	Unknown
(Use as many sheets as necessary)			
Sheet	1	of	2
Attorney Docket No: AC-26-US			

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
		3,480,714	11-25-1969	Werner Lincoln Harvey	
		6,703,392	03-09-2004	Actelion Pharmaceuticals Ltd.	
		7,192,950	03-20-2007	Actelion Pharmaceuticals Ltd.	
		20090082394	03-26-2009	Actelion Pharmaceuticals Ltd.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²
		WO98/005352	02-12-1998	The Scripps Research Institute	
		WO98/23593	06-04-1998	Pfizer US	
		WO99/58533	11-18-1999	SmithKline Beecham PLC	
		WO00/29399	05-25-2000	Boehringer Ingelheim CA Ltd	
		WO00/35882	06-22-2000	Astrazeneca UK Ltd	
		WO00/047284	08-17-2000	SmithKline Beecham PLC	
		WO00/047577	08-17-2000	SmithKline Beecham PLC	
		WO00/78742	12-28-2000	Astrazeneca UK Ltd	
		WO00/78744	12-28-2000	Astrazeneca UK Ltd	
		WO01/02368	01-11-2001	Vertex Pharma US	
		WO01/008720	02-08-2001	The Board of Trustees of the Leland Stanford Junior University	
		WO01/014555	03-14-2001	Decode Genetics EHF	
		WO01/030991	05-03-2001	Decode Genetics EHF	
		WO01/040259	06-07-2001	SmithKline Beecham PLC	
		WO01/040304	06-07-2001	SmithKline Beecham PLC	
		WO01/042268	06-14-2001	SmithKline Beecham PLC	
		WO01/074162	10-11-2001	The Regents of the University of California	
		WO02/087606	11-07-2002	SRI International	
		WO02/089800	11-14-2002	SmithKline Beecham PLC	
		WO03/032991	04-24-2003	SmithKline Beecham PLC	
		WO03/037847	05-08-2003	SmithKline Beecham PLC	
		WO03/041711	05-22-2003	SmithKline Beecham PLC	
		WO03/051368	06-26-2003	SmithKline Beecham PLC	
		WO03/051871	06-26-2003	SmithKline Beecham PLC	

EXAMINER

/Zinna Davis/ (08/14/2009)

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/598,449
				Filing Date	August 30, 2006
				First Named Inventor	Aissaoui
				Art Unit	1614
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket No: AC-26-US	

		WO03/051872	06-26-2003	SmithKline Beecham PLC	
		WO03/051873	06-26-2003	SmithKline Beecham PLC	
		WO03/091219	11-06-2003	F. Hoffmann-La Roche AG	
		WO04/019881	03-11-2004	The Regents of the University of California	
		WO04/026866	04-01-2004	SmithKline Beecham PLC	
		WO04/041791	05-21-2004	SmithKline Beecham PLC	
		WO04/041807	05-21-2004	SmithKline Beecham PLC	
		WO04/041816	05-21-2004	SmithKline Beecham PLC	
		WO04/052876	06-24-2004	Janssen Pharmaceutical N.V.	
		WO04/054510	07-01-2004	Janssen Pharmaceutical N.V.	
		WO07/105177	09-20-2007	Actelion Pharmaceuticals Ltd.	
		WO07/122591	11-01-2007	Actelion Pharmaceuticals Ltd.	
		DD 204917	12-14-1983	Univ Halle Wittenberg	
		DD 258817	08-03-1988	Univ Halle Wittenberg	
		DD 261158	10-19-1988	Univ Halle Wittenberg	
		EP 0494623	07-15-1992	Glaxo Lab SA	
		JP 61 053268	03-17-1986	Hokuriku Seiyaku Co Ltd (Abstract)	
		JP 07 267961	10-17-1995	Taisho Pharmaceut Co Ltd (Abstract)	
		JP 10 095766	04-14-1998	Sanwa Kagaku Kenkyusho Co Ltd (Abstract)	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		JAEGER et al., Effects of Orexin-A on Memory Processing, Peptides, 23 (2003), 1683-1688		
		HUTCHINS et al., Solid Phase Synthesis of Tetrahydroisoquinolines & Tetrahydroimidazopyridines, Tetrahedron Letters (1996), 37, 4865-4868		
		STAHL et al., Handbook of Pharmaceutical Salts, Wiley-VCH, Weinheim, Zurich (2002), 329-350		
		TELEGDY et al., Regulatory Peptides, 104 (2002), 105-110		
		VAN DEL POL et al., J. Physiol. (2002), 541(1), 169-185		

EXAMINER

/Zinna Davis/ (08/14/2009)

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/